Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sangamo Therapeutics (SGMO) Equity Average (2016 - 2025)

Sangamo Therapeutics (SGMO) has 15 years of Equity Average data on record, last reported at $12.9 million in Q3 2025.

  • For Q3 2025, Equity Average fell 58.86% year-over-year to $12.9 million; the TTM value through Sep 2025 reached $12.9 million, down 58.86%, while the annual FY2024 figure was $52.8 million, 72.04% down from the prior year.
  • Equity Average reached $12.9 million in Q3 2025 per SGMO's latest filing, up from $12.3 million in the prior quarter.
  • Across five years, Equity Average topped out at $483.4 million in Q1 2021 and bottomed at $12.3 million in Q2 2025.
  • Average Equity Average over 5 years is $218.9 million, with a median of $284.6 million recorded in 2023.
  • Peak YoY movement for Equity Average: increased 16.88% in 2021, then crashed 85.88% in 2024.
  • A 5-year view of Equity Average shows it stood at $390.7 million in 2021, then dropped by 22.68% to $302.1 million in 2022, then tumbled by 63.95% to $108.9 million in 2023, then crashed by 71.58% to $31.0 million in 2024, then crashed by 58.25% to $12.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Equity Average were $12.9 million in Q3 2025, $12.3 million in Q2 2025, and $13.8 million in Q1 2025.